Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2020

Mar 3, 2020

32254_dirs_2020-03-03_18985244-c56a-4c8f-8841-eec6a3b79df8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-02-28

Reporting Person: Lurker Nancy (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-02-28 Restricted Stock Units $0.00 A 374000.00 Acquired Common Stock (374000.00) Direct
2020-02-28 Stock Option (Right to Buy) $1.29 A 748000.00 Acquired 2030-02-28 Common Stock (748000.00) Direct

Footnotes

F1: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.

F2: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which begin March 28, 2020